Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gladskin Eczema Cream is a topical biologic treatment developed by Micreos Human Health for the management of atopic dermatitis (eczema). Its active ingredient, Micreobalance® (sr-(Methionyl Staphylococcus Simulans Polypeptide-1 Dipeptide-53 Staphylococcus Phage 2638A Polypeptide-1)), is a proprietary endolysin derived from bacteriophage technology. Endolysins are highly specific enzymes that cleave the peptidoglycan layer of the bacterial cell wall, leading to rapid lysis of the target organism. Micreobalance® specifically targets *Staphylococcus aureus*, a pathogen known to colonize the skin of eczema patients and exacerbate inflammation, while sparing the commensal bacteria of the skin microbiome. The cream is formulated to be steroid-free, fragrance-free, and hypoallergenic, and it has been evaluated in randomized, double-blind, placebo-controlled clinical trials for efficacy in mild to moderate atopic dermatitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gladskin eczema cream.